Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. (Nasdaq: INBX) is a clinical-stage biopharmaceutical company that focuses on developing a broad pipeline of novel biologic therapeutic candidates targeting oncology and rare diseases. With its proprietary modular protein engineering platforms, Inhibrx aims to create therapeutic candidates that address complex disease biology effectively. The company’s leading candidates include INBRX-109 and INBRX-106, which utilize multivalent formats to optimize agonist functions for specific targets.
One of the notable projects is INBRX-101, a recombinant human AAT-Fc fusion protein designed to treat patients with Alpha-1 Antitrypsin Deficiency (AATD). The ElevAATe trial, a randomized, controlled, double-blind, head-to-head superiority study, is currently evaluating INBRX-101 against plasma-derived AAT therapies. The trial aims to achieve sustained therapeutic levels with a less frequent dosing interval, addressing the limitations of current weekly infusions required by existing treatments. Initial results are anticipated by late 2024.
In another strategic move, Inhibrx has secured global rights for INBRX-101, as Chiesi Farmaceutici S.p.A declined the option for ex-North American rights, promising broader strategic opportunities in launching treatments for conditions like Graft versus Host Disease (GvHD) in markets such as Europe and Japan.
Additionally, the company has shown promising results in their Phase 1 trial of INBRX-109 combined with chemotherapies for advanced Ewing sarcoma, indicating a disease control rate of 76.9% among evaluated patients, with the majority achieving partial responses or stable disease.
Financially, Inhibrx is on the verge of a significant transaction with Sanofi, which involves the sale of INBRX-101 assets while spinning off its remaining pipeline into a new publicly traded entity, Inhibrx Biosciences, Inc. This move will position Inhibrx to continue advancing its other clinical programs and leverage its strong pipeline for future developments.
For more detailed information, visit their official website at www.inhibrx.com.
On November 7, 2022, Inhibrx, Inc. (Nasdaq: INBX) reported its third quarter 2022 financial results, revealing a net loss of $35.3 million, or $0.90 per share, compared to a net loss of $20.6 million, or $0.54 per share in Q3 2021. Cash and equivalents stood at $146.1 million as of September 30, 2022, significantly up from $131.3 million at the end of 2021. The company highlighted progress in its clinical programs, including potential accelerated approval for INBRX-101 and orphan drug designation for INBRX-109.
Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company, announced its participation in several significant scientific conferences including the ACoP and SITC annual meetings. At ACoP (Oct 30-Nov 2, 2022), they will present a poster on INBRX-101 for Alpha-1 Antitrypsin Deficiency. The SITC (Nov 8-12, 2022) will showcase research on a targeted cytokine. Additionally, Inhibrx will present updates on INBRX-109 for chondrosarcoma at the CTOS meeting (Nov 16-19, 2022). Presentations will be accessible via their investor website.
Inhibrx, Inc. (Nasdaq: INBX) announced potential for accelerated approval from the FDA for INBRX-101, a recombinant human AAT-Fc fusion protein, aimed at treating emphysema due to alpha-1 antitrypsin deficiency (AATD). The FDA supports the use of functional AAT serum levels as a surrogate endpoint. All patients tested in the Phase 1 study showed detectable INBRX-101 in bronchoalveolar lavage fluid. Inhibrx plans to begin a registration-enabling trial in Q1 2023, with a recent amendment to its loan agreement enabling $30 million funding upon announcing this regulatory path.
Inhibrx, a clinical-stage biopharmaceutical company, will host a live webcast on October 4, 2022, at 5:30 a.m. PT, to discuss the regulatory pathway for INBRX-101. This treatment targets alpha-1 antitrypsin deficiency (AATD), a rare disease affecting about 100,000 patients in the U.S. INBRX-101 is designed for less frequent dosing compared to current therapies. The Phase 1 study demonstrated safety and efficacy, with no severe adverse events reported. The FDA granted INBRX-101 orphan-drug designation in March 2022.
Inhibrx, Inc. (Nasdaq: INBX) announced that the European Commission has granted orphan medicinal product designation to INBRX-109 for treating chondrosarcoma, building on a positive EMA opinion. This designation can lead to benefits like reduced fees and market exclusivity. Chondrosarcoma affects about 2,800 new patients annually in the US and EU, with no approved therapies currently available. INBRX-109 is a DR5 agonist antibody, and the company has initiated a Phase 2 trial, showing promising preliminary results in prior trials.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q2 2022 financial results with a net loss of $37.7 million ($0.97 per share), up from $20.7 million ($0.55 per share) in Q2 2021. The company had $176.4 million in cash and equivalents as of June 30, 2022. Key highlights include a successful Phase 1 trial of INBRX-101 for AAT deficiency and the completion of Phase 1 dose escalation for INBRX-105. The company secured $60 million from Oxford Finance through a loan agreement.
On June 30, 2022, Inhibrx, Inc. (Nasdaq: INBX) announced the completion of Phase 1 dose escalation for its novel targeted 4-1BB agonist, INBRX-105, in combination with Keytruda®. The trial, involving 30 patients, indicated a favorable safety profile and durable responses. Additionally, the company secured $60 million in funding through its Loan Agreement with Oxford Finance, adjusting its cash balance to approximately $176 million. The next phase of trials is set to include around 90 patients, with initial results expected in early 2023.
Inhibrx, Inc. (Nasdaq: INBX) will present details on its INBRX-109 Phase 2 trial for conventional chondrosarcoma at the 2022 ASCO Annual Meeting from June 3-7, 2022. The trial aims to establish a placebo-controlled methodology for evaluating INBRX-109, a DR5 agonist antibody. Preliminary Phase 1 results showed efficacy in 89% of patients, with a median progression-free survival of 7.4 months. The presentation, led by Dr. Sant P. Chawla, will take place on June 5, 2022, from 9 a.m. to 11 a.m. CST, and the poster will be available online.
Inhibrx Inc. announces favorable topline results from a Phase 1 clinical trial of INBRX-101, a recombinant human AAT-Fc fusion protein for treating alpha-1 antitrypsin deficiency (AATD). The study involved 31 patients and showed no severe drug-related adverse events, with mild and reversible issues reported. The drug achieved an average functional alpha-1 antitrypsin (AAT) level of 40.4 µM after the third dose, surpassing the current standard of care's 17.8 µM. Inhibrx believes INBRX-101 could reduce infusion frequency significantly, offering a more convenient treatment option.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q1 2022 financial results and corporate updates on May 9, 2022. The company reported cash and equivalents of $143.5 million, an increase from $131.3 million at year-end 2021. R&D expenses rose to $24.9 million, compared to $16.4 million in Q1 2021. General and administrative expenses also increased to $5.1 million. The net loss for Q1 2022 was $31.3 million ($0.80 per share), up from $19.3 million ($0.51 per share) in Q1 2021. Recent highlights include FDA orphan-drug designation for INBRX-101 and a $130 million loan agreement amendment.
FAQ
What is the current stock price of Inhibrx Biosciences (INBX)?
What is the market cap of Inhibrx Biosciences (INBX)?
What is Inhibrx Biosciences, Inc.?
What are the main therapeutic candidates of Inhibrx?
What is INBRX-101?
What is the ElevAATe trial?
What were the results of the Phase 1 trial for INBRX-109?
What is the significance of Chiesi declining the option for INBRX-101?
What is the financial condition of Inhibrx?
What is the significance of the acquisition by Sanofi?
Will Inhibrx continue as a publicly traded company?
Where can I find more information about Inhibrx?
